The estimated Net Worth of Vanila Singh is at least $652 mil dollars as of 27 January 2022. Vanila Singh owns over 7,684 units of Biodelivery Sciences International stock worth over $200,407 and over the last 5 years he sold BDSI stock worth over $0. In addition, he makes $451,178 as Independent Director at Biodelivery Sciences International.
Vanila has made over 6 trades of the Biodelivery Sciences International stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,684 units of BDSI stock worth $42,954 on 27 January 2022.
The largest trade he's ever made was exercising 7,684 units of Biodelivery Sciences International stock on 27 January 2022 worth over $42,954. On average, Vanila trades about 3,983 units every 60 days since 2019. As of 27 January 2022 he still owns at least 35,851 units of Biodelivery Sciences International stock.
You can see the complete history of Vanila Singh stock trades at the bottom of the page.
Dr. Vanila Singh serves as Independent Director of the Company. Dr. Singh is currently a Clinical Associate Professor of Anesthesiology, Pain and Peri-operative Medicine at Stanford University School of Medicine and is a teaching mentor at Walter Reed National Military Medical Center. Dr. Singh is the immediate past Chief Medical Officer of the United States Department of Health and Human Services (HHS) and served as Chairperson of the Inter-Agency Pain Management Best Practices Task Force, chartered by Congress and involving multiple federal health agencies, professional medical organizations, and patient advocacy groups to guide the medical community and key stakeholders in optimal patient care in a growing and complex national health matter. Dr. Singh, board-certified in both anesthesiology and pain medicine, specializes in treating patients with complex chronic pain issues. She graduated from the University of California at Berkeley with a B.S. in both molecular and cell biology and economics. She received her M.D. from the George Washington University School of Medicine & Health Sciences. Dr. Singh completed her internal medicine internship at Yale University School of Medicine and her anesthesiology residency and pain medicine fellowship at Weill-Cornell New York Presbyterian Hospital, which included training at Memorial Sloan Kettering and the Hospital for Special Surgery.
As the Independent Director of Biodelivery Sciences International, the total compensation of Vanila Singh at Biodelivery Sciences International is $451,178. There are 7 executives at Biodelivery Sciences International getting paid more, with Scott Plesha having the highest compensation of $1,503,860.
Vanila Singh is 49, he's been the Independent Director of Biodelivery Sciences International since 2019. There are 13 older and 1 younger executives at Biodelivery Sciences International. The oldest executive at Biodelivery Sciences International is William Watson, 69, who is the Independent Director.
Vanila's mailing address filed with the SEC is C/O BIODELIVERY SCIENCES INT'L, INC., 4131 PARKLAKE AVE. SUITE 225, RALEIGH, NC, 27612.
Over the last 20 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott, eHealthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: